Identification

Name
Flunarizine
Accession Number
DB04841
Type
Small Molecule
Groups
Approved
Description

Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.

Structure
Thumb
Synonyms
  • 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine
  • Flunarizina
  • Flunarizinum
Product Ingredients
IngredientUNIICASInChI Key
Flunarizine dihydrochlorideC11102TO5330484-77-6RXKMOPXNWTYEHI-RDRKJGRWSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FlunarizineCapsule5 mgOralAa Pharma Inc2002-08-08Not applicableCanada
Sibelium Cap 5mgCapsule5 mgOralPharmascience Inc1990-12-312009-01-29Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-flunarizine - Cap 5mgCapsule5 mgOralNovopharm Limited1998-04-302015-10-26Canada
International/Other Brands
Flugeral (Italfarmaco) / Fluxarten (GlaxoSmithKline) / Gradient (Polifarma) / Sibelium (Janssen) / Zinasen (AtralCipan)
Categories
UNII
R7PLA2DM0J
CAS number
52468-60-7
Weight
Average: 404.4948
Monoisotopic: 404.206405252
Chemical Formula
C26H26F2N2
InChI Key
SMANXXCATUTDDT-QPJJXVBHSA-N
InChI
InChI=1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+
IUPAC Name
1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine
SMILES
FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1

Pharmacology

Indication

Used in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.

Structured Indications
Pharmacodynamics

Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity.

Mechanism of action

Flunarizine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

TargetActionsOrganism
AVoltage-dependent T-type calcium channel subunit alpha-1G
inhibitor
Human
AVoltage-dependent T-type calcium channel subunit alpha-1H
inhibitor
Human
AVoltage-dependent T-type calcium channel subunit alpha-1I
inhibitor
Human
UHistamine H1 receptor
antagonist
Human
UCalmodulinNot AvailableHuman
Absorption

85% following oral administration.

Volume of distribution
Not Available
Protein binding

99% bound to plasma proteins

Metabolism

Hepatic, to two metabolites via N-dealylation and hydroxylation.

Route of elimination
Not Available
Half life

18 days

Clearance
Not Available
Toxicity

-Flunarizine should be used with care in patients with depression or those being prescribed other agents, such as phenothiazines, concurrently, which may cause extrapyramidal side-effects. -Acute overdosage has been reported and the observed symptoms were sedation, agitation and tachycardia. -Treatment of acute overdosage consists of charcoal administration, induction of emesis or gastric lavage, and supportive measures. No specific antidote is known.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Flunarizine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Flunarizine.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Flunarizine.Vet Approved
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Flunarizine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Flunarizine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Flunarizine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Flunarizine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Flunarizine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Flunarizine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Flunarizine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Flunarizine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Flunarizine.Approved, Illicit
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Flunarizine.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Flunarizine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flunarizine.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Flunarizine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Flunarizine.Approved
AmobarbitalThe metabolism of Flunarizine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Flunarizine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Flunarizine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Amperozide.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Flunarizine.Approved, Illicit, Investigational
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Flunarizine.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Flunarizine.Approved, Investigational
ApalutamideThe serum concentration of Flunarizine can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe metabolism of Flunarizine can be increased when combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flunarizine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Flunarizine.Investigational
ArtemetherThe metabolism of Flunarizine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Flunarizine.Approved
AtomoxetineThe metabolism of Flunarizine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Azaperone.Investigational, Vet Approved
AzelastineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe metabolism of Flunarizine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Flunarizine.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Flunarizine.Experimental
BarbexacloneThe metabolism of Flunarizine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Flunarizine can be increased when combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Flunarizine is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Benzocaine.Approved, Investigational
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Flunarizine.Approved, Investigational
BenzphetamineBenzphetamine may decrease the sedative activities of Flunarizine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Flunarizine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineFlunarizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Flunarizine.Approved, Investigational
BetaxololThe metabolism of Flunarizine can be decreased when combined with Betaxolol.Approved, Investigational
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Flunarizine.Approved, Investigational
BortezomibThe metabolism of Flunarizine can be decreased when combined with Bortezomib.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Flunarizine.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Flunarizine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Flunarizine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Flunarizine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Flunarizine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Flunarizine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Flunarizine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Flunarizine.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Flunarizine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Bupivacaine.Approved, Investigational
BuprenorphineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Flunarizine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Flunarizine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flunarizine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Flunarizine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Flunarizine is combined with Butamben.Approved, Withdrawn
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Flunarizine.Approved
ButethalThe risk or severity of adverse effects can be increased when Flunarizine is combined with Butethal.Approved, Illicit
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Flunarizine.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flunarizine.Approved, Illicit, Vet Approved
CaffeineThe metabolism of Flunarizine can be decreased when combined with Caffeine.Approved
Calcium AcetateThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Flunarizine.Withdrawn
CanertinibThe risk or severity of adverse effects can be increased when Flunarizine is combined with Canertinib.Investigational
CapecitabineThe metabolism of Flunarizine can be decreased when combined with Capecitabine.Approved, Investigational
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Flunarizine.Experimental
CarbamazepineThe serum concentration of Flunarizine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Flunarizine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Flunarizine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Flunarizine.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Flunarizine.Approved, Investigational
CaseinThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Flunarizine.Approved
CelecoxibThe metabolism of Flunarizine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Flunarizine can be increased when it is combined with Ceritinib.Approved
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Flunarizine.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Flunarizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Flunarizine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flunarizine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Flunarizine can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Flunarizine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flunarizine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Flunarizine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Flunarizine can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Flunarizine.Approved
CholecalciferolThe metabolism of Flunarizine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Flunarizine.Approved, Investigational
CimetidineThe serum concentration of Flunarizine can be increased when it is combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Flunarizine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Flunarizine can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Flunarizine can be decreased when combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Flunarizine.Approved
ClobazamThe metabolism of Flunarizine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Flunarizine is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Flunarizine can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Flunarizine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Flunarizine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Flunarizine is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Flunarizine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flunarizine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Flunarizine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Flunarizine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Flunarizine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Flunarizine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Flunarizine.Approved, Illicit
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Flunarizine.Investigational
CrisaboroleThe metabolism of Flunarizine can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Flunarizine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Flunarizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flunarizine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Flunarizine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Flunarizine.Approved
Cyproterone acetateThe serum concentration of Flunarizine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Flunarizine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Flunarizine.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Flunarizine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Flunarizine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Flunarizine can be increased when it is combined with Darunavir.Approved
DeferasiroxThe serum concentration of Flunarizine can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Flunarizine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Flunarizine.Approved
DesipramineThe metabolism of Flunarizine can be decreased when combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Flunarizine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flunarizine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Flunarizine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Flunarizine.Approved, Illicit, Investigational, Vet Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Flunarizine.Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Flunarizine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Flunarizine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Flunarizine.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Flunarizine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Flunarizine.Approved
DiphenhydramineThe metabolism of Flunarizine can be decreased when combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Flunarizine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Flunarizine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Flunarizine can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Flunarizine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Flunarizine.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be decreased when it is combined with Flunarizine.Approved, Investigational
DoxorubicinThe metabolism of Flunarizine can be decreased when combined with Doxorubicin.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Flunarizine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved, Illicit
DronedaroneThe metabolism of Flunarizine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Flunarizine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Flunarizine can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ecgonine.Experimental, Illicit
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Flunarizine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Flunarizine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Flunarizine.Approved
EliglustatThe metabolism of Flunarizine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Flunarizine.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Flunarizine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Flunarizine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flunarizine.Approved, Investigational
EthanolFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Flunarizine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Flunarizine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Flunarizine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Flunarizine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Flunarizine can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Flunarizine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flunarizine.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Flunarizine.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Flunarizine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flunarizine is combined with Flibanserin.Approved, Investigational
FloxuridineThe metabolism of Flunarizine can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Flunarizine can be decreased when combined with Fluconazole.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Flunarizine.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fludiazepam.Approved, Illicit
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunarizine is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Flunarizine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Flunarizine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Flunarizine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flunarizine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flunarizine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Flunarizine.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Flunarizine.Experimental
FluvastatinThe metabolism of Flunarizine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Flunarizine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe therapeutic efficacy of Flunarizine can be increased when used in combination with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Flunarizine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Flunarizine is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Flunarizine.Approved, Illicit, Investigational
GemfibrozilThe metabolism of Flunarizine can be decreased when combined with Gemfibrozil.Approved
GepefrineGepefrine may decrease the sedative activities of Flunarizine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Flunarizine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Glutethimide.Approved, Illicit
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Flunarizine.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Flunarizine.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Flunarizine.Approved, Investigational
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Flunarizine.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Flunarizine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Flunarizine can be decreased when combined with Haloperidol.Approved
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Flunarizine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Flunarizine is combined with Heroin.Approved, Illicit, Investigational
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Flunarizine.Approved, Investigational
HexobarbitalThe metabolism of Flunarizine can be increased when combined with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flunarizine.Approved, Investigational
HydrocodoneFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flunarizine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Flunarizine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Iloperidone.Approved
ImipramineThe metabolism of Flunarizine can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Flunarizine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Flunarizine is combined with Indiplon.Investigational
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Flunarizine.Withdrawn
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Flunarizine.Approved
IrbesartanThe metabolism of Flunarizine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Flunarizine can be decreased when it is combined with Isavuconazole.Approved, Investigational
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Flunarizine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Flunarizine.Approved, Vet Approved
IsoniazidThe metabolism of Flunarizine can be decreased when combined with Isoniazid.Approved, Investigational
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Flunarizine.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Flunarizine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Flunarizine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Flunarizine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Flunarizine.Approved, Investigational
LeflunomideThe metabolism of Flunarizine can be decreased when combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flunarizine.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Flunarizine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Flunarizine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Flunarizine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flunarizine.Approved
LidocaineThe metabolism of Flunarizine can be decreased when combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Flunarizine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Flunarizine is combined with Lithium.Approved
LobeglitazoneThe metabolism of Flunarizine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Flunarizine is combined with Lofentanil.Illicit
LopinavirThe metabolism of Flunarizine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Flunarizine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Flunarizine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flunarizine.Approved
LorcaserinThe metabolism of Flunarizine can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Flunarizine is combined with Lormetazepam.Approved
LosartanThe metabolism of Flunarizine can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Flunarizine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Flunarizine.Approved
LumacaftorThe serum concentration of Flunarizine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Flunarizine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Flunarizine.Approved, Investigational
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Flunarizine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Flunarizine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Flunarizine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe therapeutic efficacy of Flunarizine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Flunarizine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Flunarizine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Flunarizine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Flunarizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Flunarizine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Flunarizine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Melperone.Approved, Investigational
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Flunarizine.Experimental
MephedroneMephedrone may decrease the sedative activities of Flunarizine.Investigational
MephentermineMephentermine may decrease the sedative activities of Flunarizine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flunarizine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Flunarizine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Flunarizine.Approved
MethadoneThe metabolism of Flunarizine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Flunarizine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Flunarizine.Approved, Vet Approved
MethohexitalThe metabolism of Flunarizine can be increased when combined with Methohexital.Approved
MethotrimeprazineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Flunarizine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methylecgonine.Experimental
MethylphenobarbitalThe metabolism of Flunarizine can be increased when combined with Methylphenobarbital.Approved
MetoprololThe metabolism of Flunarizine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineFlunarizine may increase the sedative activities of Metyrosine.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Flunarizine.Experimental
MexiletineThe metabolism of Flunarizine can be decreased when combined with Mexiletine.Approved, Investigational
MianserinThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Mianserin.Approved, Investigational
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Flunarizine.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Flunarizine.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Flunarizine.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative activities of Flunarizine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Flunarizine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Flunarizine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Flunarizine is combined with Milnacipran.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Flunarizine.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved, Investigational
MirabegronThe metabolism of Flunarizine can be decreased when combined with Mirabegron.Approved
MirtazapineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may decrease the sedative activities of Flunarizine.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Molindone.Approved
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Flunarizine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Flunarizine.Approved, Investigational
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Flunarizine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved, Investigational
NafcillinThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Flunarizine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flunarizine.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Flunarizine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Nefazodone.Approved, Withdrawn
NevirapineThe metabolism of Flunarizine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Flunarizine can be decreased when combined with Nicardipine.Approved, Investigational
NicotineThe metabolism of Flunarizine can be decreased when combined with Nicotine.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Flunarizine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Flunarizine.Investigational
NilotinibThe metabolism of Flunarizine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Flunarizine.Approved
NitroprussideFlunarizine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Flunarizine.Approved, Vet Approved
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Flunarizine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Flunarizine.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Flunarizine.Approved, Vet Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flunarizine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunarizine.Approved
OmeprazoleThe metabolism of Flunarizine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Flunarizine.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Flunarizine is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Flunarizine can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Flunarizine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Flunarizine can be decreased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flunarizine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Oxethazaine.Approved, Investigational
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Flunarizine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Flunarizine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flunarizine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Flunarizine.Approved, Investigational, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Flunarizine.Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Flunarizine.Approved
PanobinostatThe serum concentration of Flunarizine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe metabolism of Flunarizine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Flunarizine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Flunarizine is combined with Penfluridol.Experimental
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Flunarizine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flunarizine.Approved, Vet Approved
PentobarbitalThe metabolism of Flunarizine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
PerazineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Flunarizine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flunarizine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Flunarizine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Flunarizine is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Flunarizine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Flunarizine is combined with Phenoxyethanol.Approved
PhenterminePhentermine may decrease the sedative activities of Flunarizine.Approved, Illicit
PhenytoinThe therapeutic efficacy of Flunarizine can be increased when used in combination with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Flunarizine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Flunarizine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Piritramide.Approved, Investigational
PitolisantThe serum concentration of Flunarizine can be decreased when it is combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Flunarizine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Pomalidomide.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Flunarizine.Approved, Investigational, Vet Approved
PramipexoleFlunarizine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Flunarizine is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Flunarizine.Approved
PregabalinThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Prilocaine.Approved
PrimidoneThe metabolism of Flunarizine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flunarizine.Approved, Vet Approved
PromazineThe metabolism of Flunarizine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Flunarizine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Flunarizine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Flunarizine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Flunarizine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Flunarizine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Flunarizine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Flunarizine.Approved
PyrimethamineThe metabolism of Flunarizine can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Flunarizine.Experimental
QuazepamThe serum concentration of Flunarizine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flunarizine.Approved
QuinidineThe metabolism of Flunarizine can be decreased when combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Flunarizine can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Raclopride.Investigational
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Flunarizine.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Flunarizine.Approved, Investigational
RanolazineThe metabolism of Flunarizine can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Flunarizine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Flunarizine.Approved, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Flunarizine.Approved, Investigational
RifampicinThe metabolism of Flunarizine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Flunarizine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Flunarizine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Flunarizine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative activities of Flunarizine.Investigational
RitonavirThe metabolism of Flunarizine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Flunarizine can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Romifidine.Vet Approved
RopiniroleFlunarizine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ropivacaine.Approved
RotigotineFlunarizine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Flunarizine can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Flunarizine.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Flunarizine.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Flunarizine.Approved, Investigational, Vet Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flunarizine.Approved, Investigational
SecobarbitalThe metabolism of Flunarizine can be increased when combined with Secobarbital.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Sepranolone.Investigational
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Flunarizine.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Flunarizine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Flunarizine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Flunarizine.Approved, Vet Approved
SildenafilThe metabolism of Flunarizine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Flunarizine.Approved
SimeprevirThe metabolism of Flunarizine can be decreased when combined with Simeprevir.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Flunarizine.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Flunarizine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
SorafenibThe metabolism of Flunarizine can be decreased when combined with Sorafenib.Approved, Investigational
StiripentolThe metabolism of Flunarizine can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flunarizine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Flunarizine.Approved
SulfadiazineThe metabolism of Flunarizine can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Flunarizine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Flunarizine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Sultopride.Experimental
SuvorexantFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Flunarizine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tasimelteon.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Flunarizine.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Flunarizine.Approved, Investigational
Tenofovir disoproxilThe metabolism of Flunarizine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Flunarizine.Approved
TerbinafineThe metabolism of Flunarizine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Flunarizine.Approved
TeriflunomideThe serum concentration of Flunarizine can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tetrodotoxin.Investigational
ThalidomideFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Flunarizine can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Flunarizine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Flunarizine can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Flunarizine can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiotepaThe metabolism of Flunarizine can be decreased when combined with Thiotepa.Approved, Investigational
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Flunarizine.Approved
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Flunarizine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Flunarizine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tiapride.Approved, Investigational
TicagrelorThe metabolism of Flunarizine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Flunarizine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tilidine.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Flunarizine.Approved
TipranavirThe metabolism of Flunarizine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Flunarizine.Approved, Investigational
TolbutamideThe metabolism of Flunarizine can be decreased when combined with Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Flunarizine.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Flunarizine.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Flunarizine.Approved, Investigational, Vet Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Flunarizine.Approved
TopiroxostatThe metabolism of Flunarizine can be decreased when combined with Topiroxostat.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Flunarizine.Approved, Investigational
TranylcypromineThe metabolism of Flunarizine can be decreased when combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Flunarizine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Flunarizine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flunarizine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Flunarizine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Triflupromazine.Approved, Vet Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Flunarizine.Experimental
TrimethoprimThe metabolism of Flunarizine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Flunarizine.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Flunarizine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Flunarizine.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Flunarizine.Investigational
Valproic AcidThe metabolism of Flunarizine can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Flunarizine can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Flunarizine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Flunarizine can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Flunarizine.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Flunarizine is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Flunarizine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Flunarizine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Xylazine.Vet Approved
ZafirlukastThe metabolism of Flunarizine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Flunarizine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Flunarizine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Flunarizine is combined with Zolazepam.Vet Approved
ZolpidemFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Flunarizine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Flunarizine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Flunarizine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Flunarizine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference

Matthew Peterson, Julius Remenar, Carlos Sanrame, "NOVEL FLUNARIZINE SALT FORMS AND METHODS OF MAKING AND USING THE SAME." U.S. Patent US20080200474, issued August 21, 2008.

US20080200474
General References
Not Available
External Links
Human Metabolome Database
HMDB0015589
KEGG Drug
D01303
PubChem Compound
941361
PubChem Substance
46507129
ChemSpider
819216
BindingDB
50017702
ChEBI
135652
ChEMBL
CHEMBL30008
Therapeutic Targets Database
DAP000142
PharmGKB
PA164776636
Drugs.com
Drugs.com Drug Page
Wikipedia
Flunarizine
ATC Codes
N07CA03 — Flunarizine
AHFS Codes
  • 28:32.92 — Antimigraine Agents, Miscellaneous
  • 04:04.16 — Piperazine Derivatives

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHuman Volunteers / Migraines1
4CompletedTreatmentChronic Migraine1
4CompletedTreatmentSchizophrenic Disorders1
Not AvailableRecruitingTreatmentMigraines1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral5 mg
Prices
Unit descriptionCostUnit
Apo-Flunarizine 5 mg Capsule0.75USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)251.5Janssen, P.A.J.; U.S. Patent 3,773,939; November 20, 1973; assigned to Janssen Pharmaceutica N.V.
logP5.78BIOBYTE (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00168 mg/mLALOGPS
logP5.3ALOGPS
logP6.17ChemAxon
logS-5.4ALOGPS
pKa (Strongest Basic)7.6ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity120.3 m3·mol-1ChemAxon
Polarizability44.2 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9574
Blood Brain Barrier+0.9789
Caco-2 permeable+0.5893
P-glycoprotein substrateSubstrate0.7209
P-glycoprotein inhibitor IInhibitor0.9266
P-glycoprotein inhibitor IINon-inhibitor0.6563
Renal organic cation transporterInhibitor0.7605
CYP450 2C9 substrateNon-substrate0.8855
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.7208
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9229
CYP450 2D6 inhibitorInhibitor0.9323
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9034
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7304
Ames testNon AMES toxic0.8902
CarcinogenicityNon-carcinogens0.9422
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3271 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5261
hERG inhibition (predictor II)Inhibitor0.7549
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0090100000-cef5de63fdba54327f14

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Styrenes / N-alkylpiperazines / Fluorobenzenes / Aralkylamines / Aryl fluorides / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organofluorides / Hydrocarbon derivatives
Substituents
Diphenylmethane / Styrene / Fluorobenzene / Halobenzene / Aralkylamine / N-alkylpiperazine / Aryl fluoride / Aryl halide / 1,4-diazinane / Piperazine
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1G
Uniprot ID
O43497
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1G
Molecular Weight
262468.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Uebele VN, Nuss CE, Fox SV, Garson SL, Cristescu R, Doran SM, Kraus RL, Santarelli VP, Li Y, Barrow JC, Yang ZQ, Schlegel KA, Rittle KE, Reger TS, Bednar RA, Lemaire W, Mullen FA, Ballard JE, Tang C, Dai G, McManus OB, Koblan KS, Renger JJ: Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93. doi: 10.1007/s12013-009-9057-4. Epub 2009 Jul 7. [PubMed:19582593]
  4. Santi CM, Cayabyab FS, Sutton KG, McRory JE, Mezeyova J, Hamming KS, Parker D, Stea A, Snutch TP: Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403. [PubMed:11784784]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1H
Uniprot ID
O95180
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight
259160.2 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  4. Uebele VN, Nuss CE, Fox SV, Garson SL, Cristescu R, Doran SM, Kraus RL, Santarelli VP, Li Y, Barrow JC, Yang ZQ, Schlegel KA, Rittle KE, Reger TS, Bednar RA, Lemaire W, Mullen FA, Ballard JE, Tang C, Dai G, McManus OB, Koblan KS, Renger JJ: Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93. doi: 10.1007/s12013-009-9057-4. Epub 2009 Jul 7. [PubMed:19582593]
  5. Santi CM, Cayabyab FS, Sutton KG, McRory JE, Mezeyova J, Hamming KS, Parker D, Stea A, Snutch TP: Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403. [PubMed:11784784]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1I
Uniprot ID
Q9P0X4
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1I
Molecular Weight
245100.8 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Uebele VN, Nuss CE, Fox SV, Garson SL, Cristescu R, Doran SM, Kraus RL, Santarelli VP, Li Y, Barrow JC, Yang ZQ, Schlegel KA, Rittle KE, Reger TS, Bednar RA, Lemaire W, Mullen FA, Ballard JE, Tang C, Dai G, McManus OB, Koblan KS, Renger JJ: Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93. doi: 10.1007/s12013-009-9057-4. Epub 2009 Jul 7. [PubMed:19582593]
  4. Santi CM, Cayabyab FS, Sutton KG, McRory JE, Mezeyova J, Hamming KS, Parker D, Stea A, Snutch TP: Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403. [PubMed:11784784]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Taylor JE, Defeudis FV: Interactions of verapamil, D 600, flunarizine and nifedipine with cerebral histamine-receptors. Neurochem Int. 1986;9(3):379-81. [PubMed:20493137]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on September 27, 2007 07:47 / Updated on April 23, 2018 23:09